Archie Goodburn, a 24-year-old British swimmer and brain cancer patient, is rallying for increased government support for those affected by his rare condition. With a rare, inoperable form of brain cancer known as oligodendroglioma, Goodburn has experienced a life-altering journey marked by medical challenges and a determination to advocate for change. His calls come in the wake of limited progress in drug development and funding for brain cancer research in the UK.
A Life Changed by Diagnosis
Two years ago, Goodburn was on the brink of qualifying for the Paris Olympics when he began to experience alarming symptoms during training. He reported episodes of weakness, numbness, and intense fear that left him questioning his future in the sport. After narrowly missing qualification in April 2024, doctors diagnosed him with three oligodendrogliomas, a rare type of brain tumour that accounts for approximately 3% of all brain cancer cases.
Despite the grim prognosis, Goodburn’s fortunes changed with the introduction of Vorasidenib, a breakthrough treatment that provided him with a renewed opportunity to compete. The drug has allowed him to defer the need for chemotherapy and radiotherapy, which could have severely impacted both his athletic career and his studies in chemical engineering. “Vorasidenib has bought me time, but I need more options,” he asserted. “One new drug in 20 years is simply not enough.”
The Funding Crisis in Brain Cancer Research
Goodburn’s story is part of a larger narrative surrounding the funding crisis in brain cancer research. Although brain cancer is the leading cause of cancer deaths among children and young adults under 40, it has received a mere 1% of the UK government’s national cancer research budget since 2002. The lack of funding hampers the translation of groundbreaking research into accessible clinical trials, often referred to as the “valley of death” in the medical community.
The all-party parliamentary group on brain tumours recently highlighted this gap, attributing it to a risk-averse funding system that stifles innovation. Even when funding is available, regulatory hurdles often prevent it from reaching the patients who need it most. Goodburn notes that limited access to trials and treatments can mean the difference between life and death, urging the government to take immediate action.
A Call for Change
In light of these challenges, Goodburn and the Brain Cancer Justice campaign are vocally advocating for the release of the remainder of the £40 million pledged by the government in 2018 for brain cancer research. They are also demanding the appointment of a dedicated brain cancer lead within the government, increased genome sequencing for patients, and the establishment of a “right to try” policy that would allow patients access to potentially life-saving treatments.
The Department of Health and Social Care has acknowledged the need for enhanced research into brain tumours and expressed a commitment to ensuring patient access to innovative new medicines. However, Goodburn is determined to hold the government accountable, stating, “I won’t stop campaigning until my last breath.”
Balancing Advocacy and Competition
As he prepares to compete in the upcoming Commonwealth Games in Glasgow, Goodburn’s journey is not just about personal achievement; it’s also a platform for advocacy. He recalls watching the 2014 Commonwealth Games as a child and feels a deep sense of responsibility to use his voice for those who are often overlooked in the healthcare system.
The dual demands of training and campaigning have been challenging, but Goodburn views his activism as integral to his recovery. “Campaigning is a treatment of its own,” he said. “It drives me to work harder, not just for myself but for others who are facing similar struggles.”
Why it Matters
Goodburn’s story sheds light on the urgent need for reform in brain cancer research funding and treatment accessibility. The disparities in care that he highlights are not just statistics; they represent real lives affected by a lack of adequate support. His commitment to advocacy serves as a beacon of hope for many, illustrating that even in the face of adversity, individuals can effect meaningful change. The government’s response to his campaign could pave the way for a more equitable healthcare system that prioritises the needs of all patients, particularly those battling devastating conditions like brain cancer.
